Lonza Group AG Earnings Calls
| Release date | Jul 23, 2025 |
| EPS estimate | $8.90 |
| EPS actual | $7.64 |
| EPS Surprise | -14.16% |
| Revenue estimate | 4.396B |
| Revenue actual | 4.501B |
| Revenue Surprise | 2.38% |
| Release date | May 08, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | May 14, 2025 |
| EPS estimate | $8.79 |
| EPS actual | $4.74 |
| EPS Surprise | -46.08% |
| Revenue estimate | 3.883B |
| Revenue actual | 3.872B |
| Revenue Surprise | -0.278% |
| Release date | Jan 29, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Lonza Group AG
Below you can see how LZAGF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jan 29, 2025 |
| Price on release | $639.25 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jan 23, 2025 | $648.73 |
| Jan 24, 2025 | $645.45 |
| Jan 27, 2025 | $646.42 |
| Jan 28, 2025 | $672.54 |
| Jan 29, 2025 | $639.25 |
| Jan 30, 2025 | $665.38 |
| Jan 31, 2025 | $649.00 |
| Feb 03, 2025 | $657.35 |
| Feb 04, 2025 | $679.15 |
| 4 days before | -1.46% |
| 4 days after | 6.24% |
| On release day | 0% |
| Change in period | 4.69% |
| Release date | May 14, 2025 |
| Price on release | $682.15 |
| EPS estimate | $8.79 |
| EPS actual | $4.74 |
| EPS surprise | -46.08% |
| Date | Price |
|---|---|
| May 08, 2025 | $707.35 |
| May 09, 2025 | $711.25 |
| May 12, 2025 | $692.60 |
| May 13, 2025 | $692.60 |
| May 14, 2025 | $682.15 |
| May 15, 2025 | $683.15 |
| May 16, 2025 | $689.50 |
| May 19, 2025 | $674.95 |
| May 20, 2025 | $699.45 |
| 4 days before | -3.56% |
| 4 days after | 2.54% |
| On release day | 0.147% |
| Change in period | -1.12% |
| Release date | May 08, 2025 |
| Price on release | $707.35 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 02, 2025 | $740.00 |
| May 05, 2025 | $734.86 |
| May 06, 2025 | $699.65 |
| May 07, 2025 | $707.35 |
| May 08, 2025 | $707.35 |
| May 09, 2025 | $711.25 |
| May 12, 2025 | $692.60 |
| May 13, 2025 | $692.60 |
| May 14, 2025 | $682.15 |
| 4 days before | -4.41% |
| 4 days after | -3.56% |
| On release day | 0.551% |
| Change in period | -7.82% |
| Release date | Jul 23, 2025 |
| Price on release | $735.25 |
| EPS estimate | $8.90 |
| EPS actual | $7.64 |
| EPS surprise | -14.16% |
| Date | Price |
|---|---|
| Jul 17, 2025 | $721.50 |
| Jul 18, 2025 | $715.65 |
| Jul 21, 2025 | $705.70 |
| Jul 22, 2025 | $708.15 |
| Jul 23, 2025 | $735.25 |
| Jul 24, 2025 | $692.87 |
| Jul 25, 2025 | $737.41 |
| Jul 28, 2025 | $718.05 |
| Jul 29, 2025 | $724.10 |
| 4 days before | 1.91% |
| 4 days after | -1.52% |
| On release day | -5.76% |
| Change in period | 0.360% |
Lonza Group AG Earnings Call Transcript Summary of Q2 2025
In H1 2025, Lonza demonstrated strong performance with CHF 3.6 billion in sales, a 19% increase compared to 2024, and raised its full-year guidance for CDMO sales growth to 20-21%. The core EBITDA margin for the CDMO business reached over 30%. The company revealed its successful transition to a new operational model and outlined ongoing investments in growth projects, particularly in Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Future outlook remains positive despite potential macroeconomic challenges, with confidence in maintaining strong customer relationships and demand across their platforms. The exit from the Capsules and Health Ingredients business is progressing as planned.
Sign In
Buy LZAGF